Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries

Papers of special note have been highlighted as: • of interest •• of considerable interest.

References

• 1 Schellekens H. How similar do ‘biosimilars’ need to be? Nat. Biotechnol. 22(11), 1357–1359 (2004).•• Review of issues related to the requirements by the EMA for a marketing authorization of ‘biosimilars’.
  Medline CASGoogle Scholar
• 2 Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J. Oncol. Pharm. Pract. 18(2), 171–179 (2012).
  MedlineGoogle Scholar
• 3 Abraham I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Exp. Opin. Drug Safe. 11(5), 819–840 (2012). • Review of the available safety evidence shows that the three agents (Binocrit®, epoetin alfa, Sandoz, Holzkirchen, Germany; Retacrit®, epoetin zeta, Hospira, IL, USA; and Eporatio®, epoetin theta, Ratiopharm, Ulm, Germany), approved by the EMA, have similar safety profiles.
  Medline CASGoogle Scholar
• 4 Ebbers HC, Crow SA, Vulto AG et al. Interchangeability, immunogenicity and biosimilars. Nat. Biotechnol. 30(12), 1186–1190 (2012).
  Medline CASGoogle Scholar
• 5 Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Euro. J. Haematol. 86(4), 277–288 (2011).
  Medline CASGoogle Scholar
• 6 Aapro MS. What do prescribers think of biosimilars? Target. Oncol. 7(Suppl. 1), S51–55 (2012). • Informative review of the lay concerns that clinicians have about biosimilars.
  MedlineGoogle Scholar
• 7 Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2(Suppl. 1), i27–i36 (2009).
  Medline CASGoogle Scholar
• 8 Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann. Oncol. 19(3), 411–419 (2008).•• Authors argue that biosimilars should provide cost savings and greater accessibility to biopharmaceuticals. A thorough knowledge surrounding biosimilars will ensure appropriate use.
  Medline CASGoogle Scholar
• 9 Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin. Nephrol. 72(5), 380–390 (2009).
  Medline CASGoogle Scholar
• 10 Weigang-Kohler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie 32(4), 168–174 (2009).
  MedlineGoogle Scholar
• 11 Wizemann V, Rutkowski B, Baldamus C et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr. Med. Res. Opin. 24(3), 625–637 (2008).
  Medline CASGoogle Scholar
• 12 Krivoshiev S. Todorov VV, Manitius J et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr. Med. Res. Opin. 24(5), 1407–1415 (2008).
  Medline CASGoogle Scholar
• 13 Gertz B, Kohler E, Kesp P et al. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta. Curr. Med. Res. Opin. 26(10), 2393–2402 (2010).
  Medline CASGoogle Scholar
• 14 Tjulandin SA, Bias P, Elsässer R et al. Epoetin theta in anaemic cancer. patients receiving platinum-based chemotherapy: a randomised controlled trial. Arch. Drug Inf. 3(3), 45–53 (2010).
  Medline CASGoogle Scholar
• 15 Tjulandin SA, Bias P, Elsässer R et al. Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial. Arch. Drug Inf. 4(3), 33–41 (2011).
  Medline CASGoogle Scholar
• 16 Jelkmann W. Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am. J. Hematol. 85(10), 771–780 (2010).
  MedlineGoogle Scholar
• 17 Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 71(12), 1527–1536 (2011).
  Medline CASGoogle Scholar
• 18 Aapro M, Cornes P, Sun D, Abraham I. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther. Adv. Med. Oncol. 4(3), 95–105 (2012).•• Economic analysis showing that managing chemotherapy-induced anemia with biosimilar epoetin alfa is consistently cost efficient over treatment with originator epoetin alfa, epoetin beta and darbepoetin alfa under both fixed and weight-based dosing scenarios.
  MedlineGoogle Scholar
• 19 Ludwig H, Aapro M, Bokemeyer C et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur. J. Cancer 45(9), 1603–1615 (2009).• Retrospective pharmacoepidemiologic study of 2192 patients from 207 centers examining anaemia management in cancer patients treated with erythropoiesis-stimulating agents in Europe.
  MedlineGoogle Scholar
• 20 Eurostat European statistics. http://epp.uerostat.ec.europa.eu/tgm/table.do?tab=table&language=en&pcode=tps00001&tableSelection=1&footnotes=yes&labeling=labels&plugin=1
  Google Scholar
• 21 Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
  Medline CASGoogle Scholar
• 22 Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104(3), 634–641 (2004).
  Medline CASGoogle Scholar
• 23 Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783–792 (2001).
  Medline CASGoogle Scholar
• 24 Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765–781 (2010).
  Medline CASGoogle Scholar
• 25 Abraham I, MacDonald K. Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars 2, 13–25 (2012).• Review of the available evidence on the clinically efficacy and safety of Binocrit, the biosimilar under consideration in this present simulation study.
  CASGoogle Scholar
• 26 Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 12(10), 933–980 (2011).•• Expert opinion from healthcare professionals, policy-makers and cancer survivors on the barriers and solutions to delivering affordable cancer care.
  MedlineGoogle Scholar
• 27 Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat. Biotechnol. 28(1), 28–31 (2010).
  Medline CASGoogle Scholar
• 28 Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1(6), 457–462 (2002).
  Medline CASGoogle Scholar
• 29 Schellekens H. The first biosimilar epoetin: but how similar is it? Clin. J. Am. Soc. Nephrol. 3(1), 174–178 (2008).
  MedlineGoogle Scholar
• 30 Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346(7), 469–475 (2002).
  Medline CASGoogle Scholar
• 31 Goldsmith D, Gesualdo L. Biosimilar epoetins in nephrology – where are we now? Eur. Nephrol. 6(1), 21–24 (2012).
  Google Scholar
• 32 IGES Institute. The competitive role of biosimilars in the German SHI market for pharmaceuticals (2010). www.baselgovernance.org/fileadmin/docs/Events/Generics_2011/14_Dr._Joerg_Windisch.pdf 
  Google Scholar
• 33 IMS Health. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape (2011). www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf 
  Google Scholar
• 34 Dalgaard K, Evers M, Santso Da Silva J. Biosimilars seven years on: where are we and what’s next? (2013). www.mckinsey.com/∼/media/mckinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/Biosimilars%20Seven%20years%20on_White%20Paper.ashx 
  Google Scholar